Praxis Precision Medicines Inc Stock News

EMBOLD data to serve as basis of efficacy and safety following discussion with the FDA EMBOLD data to serve as basis of efficacy and safety following discussion with the FDA

Clear recognition of high unmet need and urgency for the SCN2A community and plausibility of the mechanism of elsunersen

Praxis Precision Medicines shares shot skyward Friday after the company stopped an epilepsy study early due to strong effectiveness.

Successful interim analysis triggered early stop for efficacy Topline study results to be shared at the American Epilepsy Society Annual Meeting on December 6, 2025 Praxis confirms an upcoming meeting with the FDA to discuss the results and NDA path BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating ...

Praxis confirms plans to submit the essential tremor NDA for ulixacaltamide in early 2026 Praxis confirms plans to submit the essential tremor NDA for ulixacaltamide in early 2026

BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on December 1, 2025, the Compensation Committee of Praxis' Board of Directors...

Praxis Precision Medicines, Inc. is upgraded to a Strong Buy, driven by pipeline progress and positive phase 3 data for Ulixacaltamide in Essential Tremor. PRAX's Ulixacaltamide achieved primary endpoints in two phase 3 studies, positioning it as the first potential FDA-approved therapy for Essential Tremor, targeting a large unmet market. Upcoming PRAX catalysts include a pre-NDA meeting with ...

Praxis Precision Medicines, Inc. ( PRAX ) Discusses Essential3 Program and Statistical Modeling Approaches in Clinical Studies November 24, 2025 1:00 PM EST Company Participants Marcio Souza - President, CEO & Director Conference Call Participants Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division Chuck McCullogh Presentation Douglas Tsao H.C.